A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the <scp>ACTIVITY‐HF</scp> study

Abstract

In patients with HFrEF, short-term treatment with sacubitril/valsartan for 12 weeks did not result in significant benefits on peak VO₂ when compared with enalapril.